Investors in the pharma/biotech sector eagerly wait for pipeline updates as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight on the commercial potential of the candidate once it is successfully developed and commercialized.
Last week, Kamada Ltd. KMDA reported encouraging data from a pivotal phase II/III study on its human rabies immune globulin (IgG, proposed U.S. trade name: KedRAB) therapy as a post-exposure treatment for rabies. The study met its primary endpoint of non-inferiority when measured against an IgG reference product. The company plans to file a Biologics License Application (BLA) for its human rabies immune globulin with the FDA in mid 2016.
Top-line data from the study showed that the primary endpoint of non-inferiority was met with a difference of -1.8% between the two therapies. The drug was safe and well-tolerated, and no drug-related serious adverse events were observed.
As per company sources, approximately 40,000 post-exposure prophylaxis treatments are administrated annually, representing market opportunity of more than $100 million. KedRAB has the potential to tap into this market.
We note that the drug is already available in 10 countries outside the U.S. under the trade name KamRAB. Kamada is collaborating with Kedrion S.p.A for clinical development and marketing of its human rabies immune globulin drug.
Kamada has a Zacks Rank #5 (Strong Sell). Some better-ranked stocks in the health care sector are Achillion Pharmaceuticals, Inc. ACHN, Horizon Pharma plc HZNP and Corcept Therapeutics Incorporated CORT. All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment